QCLS vs VRAX

Q/C Technologies, Inc. vs Virax Biolabs Group Limited — Valuation Comparison 2026

QCLS

In Vitro & In Vivo Diagnostic Substances
Q/C Technologies, Inc.
Quality
4.0
out of 10
Value Trap
25
LOW
Price
$4.37
Last close
Models
7/13
Active
VS

VRAX

In Vitro & In Vivo Diagnostic Substances
Virax Biolabs Group Limited
Quality
1.6
out of 10
Value Trap
6
SAFE
Price
$0.19
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType QCLS Fair ValueQCLS Upside VRAX Fair ValueVRAX Upside
Bayesian DCF Intrinsic $1.21 -72.3% $0.04 -79.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.11 -97.5% $0.41 +114.7%
PWERM Option-Based $5.79 +32.5% $0.28 +125.8%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for QCLS vs VRAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

QCLS vs VRAX — Which Stock Is More Undervalued?

QCLS scores higher with a 4.0/10 quality rating vs VRAX's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Q/C Technologies, Inc. (QCLS) and Virax Biolabs Group Limited (VRAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

QCLS currently trades at $4.37 with a QOC of 4.0/10, while VRAX trades at $0.19 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).